Modality
siRNA
MOA
C5i
Target
BCL-2
Pathway
RNA Splicing
Huntington's
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Dec 2027
Phase 1Current
NCT08837215
2,972 pts·Huntington's
2022-04→2027-12·Recruiting
NCT06729658
263 pts·Huntington's
2024-11→2027-01·Not yet recruiting
3,235 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-01-089mo awayInterim· Huntington's
2027-12-241.7y awayInterim· Huntington's
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Recruit…
P1
Not yet…
Catalysts
Interim
2027-01-08 · 9mo away
Huntington's
Interim
2027-12-24 · 1.7y away
Huntington's
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08837215 | Phase 1 | Huntington's | Recruiting | 2972 | EDSS |
| NCT06729658 | Phase 1 | Huntington's | Not yet recr... | 263 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Zenonaritide | Arvinas | Phase 1/2 | BCL-2 |